Safety and Feasibility of Intradiscal Administration of Matrilin-3-Primed Adipose-Derived Mesenchymal Stromal Cell Spheroids for Chronic Discogenic Low Back Pain: Phase 1 Clinical Trial
International Journal of Molecular Sciences · 27.11.2023 · 24 (23) · 16827
DOI: 10.3390/ijms242316827 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.11.2023. Verfasst von Dong Hyun Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Spine Center, The Leon Wiltse Memorial Hospital, Suwon 16480, Republic of Korea. Hauptthemen laut MEDLINE: Low Back Pain, Intervertebral Disc, Intervertebral Disc Degeneration, Mesenchymal Stem Cells. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Korea Healthcare Technology Research & Development Project, Ministry for Health & Welfare Affairs, Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education.
Abstract (Originalsprache)
Functionally enhanced mesenchymal stromal cells participate in the repair of intervertebral disc. This study aimed to assess the safety and tolerability of intradiscal administration of matrilin-3-primed adipose-derived stromal cell (ASC) spheroids with hyaluronic acid (HA) in patients with chronic discogenic low back pain (LBP). In this single-arm, open-label phase I clinical trial, eight patients with chronic discogenic LBP were observed over 6 months. Each patient underwent a one-time intradiscal injection of 1 mL of 6.0 × 106 cells/disc combined with HA under real-time fluoroscopic guidance. Safety and feasibility were gauged using Visual Analogue Scale (VAS) pain and Oswestry Disability Index (ODI) scores and magnetic resonance imaging. All participants remained in the trial, with no reported adverse events linked to the procedure or stem cells. A successful outcome-marked by a minimum 2-point improvement in the VAS pain score and a 10-point improvement in ODI score from the start were observed in six participants. Although the modified Pfirrmann grade remained consistent across all participants, radiological improvements were evident in four patients. Specifically, two patients exhibited reduced high-intensity zones while another two demonstrated decreased disc protrusion. In conclusion, the intradiscal application of matrilin-3-primed ASC spheroids with HA is a safe and feasible treatment option for chronic discogenic LBP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Spine Center, The Leon Wiltse Memorial Hospital, Suwon 16480, Republic of Korea.
- Department of Neurosurgery, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, Republic of Korea.
- Department of Neurosurgery, Kyung Hee University, Seoul 02447, Republic of Korea.
- Department of Radiology, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, Republic of Korea.
ORCID-Profile: Dong Hyun Lee, Kwang-Sook Park, Seong Bae An, Inbo Han
Förderung
- NIEHS NIH HHS
- Korea Healthcare Technology Research & Development Project, Ministry for Health & Welfare Affairs
- Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education
Zitieren
APA
Lee, D. H., Park, K. S., Shin, H. E., Kim, S. B., Choi, H., An, S. B., Choi, H., Kim, J. P., & Han, I. (2023). Safety and Feasibility of Intradiscal Administration of Matrilin-3-Primed Adipose-Derived Mesenchymal Stromal Cell Spheroids for Chronic Discogenic Low Back Pain: Phase 1 Clinical Trial. International Journal of Molecular Sciences, 24(23), 16827. https://doi.org/10.3390/ijms242316827
Vancouver
Lee DH, Park KS, Shin HE, Kim SB, Choi H, An SB, et al. Safety and Feasibility of Intradiscal Administration of Matrilin-3-Primed Adipose-Derived Mesenchymal Stromal Cell Spheroids for Chronic Discogenic Low Back Pain: Phase 1 Clinical Trial. International Journal of Molecular Sciences. 2023;24(23):16827. doi:10.3390/ijms242316827
BibTeX
@article{Lee2023,
author = {Lee, Dong Hyun and Park, Kwang-Sook and Shin, Hae Eun and Kim, Sung Bum and Choi, Hyejeong and An, Seong Bae and Choi, Hyemin and Kim, Joo Pyung and Han, Inbo},
title = {Safety and Feasibility of Intradiscal Administration of Matrilin-3-Primed Adipose-Derived Mesenchymal Stromal Cell Spheroids for Chronic Discogenic Low Back Pain: Phase 1 Clinical Trial},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {23},
pages = {16827},
doi = {10.3390/ijms242316827}
}
EUVIMED